• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MET和脂肪酸合酶作为三阴性乳腺癌的预后生物标志物：临床研究的系统证据全景

MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.

作者信息

Jiang Weihua, Xing Xiao-Liang, Zhang Chenguang, Yi Lina, Xu Wenting, Ou Jianghua, Zhu Ning

机构信息

The Affiliated Tumor Hospital of Xinjiang Medical University, Wulumuqi, China.

Hunan University of Medicine, Huaihua, China.

出版信息

Front Oncol. 2021 May 27;11:604801. doi: 10.3389/fonc.2021.604801. eCollection 2021.

DOI:10.3389/fonc.2021.604801
PMID:34123778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8190390/
Abstract

BACKGROUND

To know the expression of Mesenchymal-Epithelial Transition factor (MET) and Fatty Acid Synthase (FASN) in Triple Negative Breast Cancer (TNBC) patients, as well as its relationship with clinical pathological characteristic and prognosis.

METHODS

we used immunohistochemistry staining to detect the expression of MET and FASN for those 218 TNBC patients, and analyze their relationship with the clinical pathological characteristic and prognosis.

RESULTS

130 and 65 out of 218 TNBC patients were positive for MET in the cancer and adjacent tissues respectively. 142 and 30 out of 218 TNBC patients were positive for FASN in the cancer and adjacent tissues respectively. Positive expression of MET and FASN were significantly correlated with lymph node metastasis, pathological TNM, and pathological Stage. In addition, the positive expression of MET and FASN were correlated with recurrence and metastasis. The combined use of MET and FASN can better predict the survival condition.

CONCLUSIONS

Our results indicated that MET and FASN showed good predictive ability for TNBC. Combined use of MET and FASN were recommended in order to make a more accurate prognosis for TNBC.

摘要

背景

了解间充质-上皮转化因子（MET）和脂肪酸合酶（FASN）在三阴性乳腺癌（TNBC）患者中的表达情况，及其与临床病理特征和预后的关系。

方法

我们采用免疫组织化学染色法检测了218例TNBC患者中MET和FASN的表达，并分析了它们与临床病理特征和预后的关系。

结果

218例TNBC患者中，分别有130例和65例在癌组织和癌旁组织中MET呈阳性。218例TNBC患者中，分别有142例和30例在癌组织和癌旁组织中FASN呈阳性。MET和FASN的阳性表达与淋巴结转移、病理TNM分期及病理分级显著相关。此外，MET和FASN的阳性表达与复发和转移相关。联合使用MET和FASN能更好地预测生存情况。

结论

我们的结果表明，MET和FASN对TNBC具有良好的预测能力。建议联合使用MET和FASN，以便对TNBC做出更准确的预后判断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff6f/8190390/4de66d1e49e5/fonc-11-604801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff6f/8190390/055687cf3d0d/fonc-11-604801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff6f/8190390/4de66d1e49e5/fonc-11-604801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff6f/8190390/055687cf3d0d/fonc-11-604801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff6f/8190390/4de66d1e49e5/fonc-11-604801-g002.jpg

相似文献

1
MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.MET和脂肪酸合酶作为三阴性乳腺癌的预后生物标志物：临床研究的系统证据全景
Front Oncol. 2021 May 27;11:604801. doi: 10.3389/fonc.2021.604801. eCollection 2021.
2
Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer.脂肪酸合酶在三阴性乳腺癌中的表达及其与临床组织病理学特征的关系
Oncotarget. 2017 Aug 10;8(43):74391-74405. doi: 10.18632/oncotarget.20152. eCollection 2017 Sep 26.
3
Fatty acid synthetase expression in triple-negative breast cancer.三阴性乳腺癌中脂肪酸合成酶的表达
J Pathol Transl Med. 2022 Mar;56(2):73-80. doi: 10.4132/jptm.2021.10.27. Epub 2022 Jan 21.
4
Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.基于列线图模型联合HIF-1α和c-myc表达预测三阴性乳腺癌术后生存率
Medicine (Baltimore). 2019 Oct;98(40):e17370. doi: 10.1097/MD.0000000000017370.
5
Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer.三阴性乳腺癌中脂肪酸合酶与脂肪分化相关蛋白表达之间的关联
Mol Clin Oncol. 2022 Apr;16(4):80. doi: 10.3892/mco.2022.2513. Epub 2022 Feb 9.
6
Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.三阴性乳腺癌中脂肪酸合酶和表皮生长因子受体抑制的临床前评估。
Clin Cancer Res. 2016 Sep 15;22(18):4687-97. doi: 10.1158/1078-0432.CCR-15-3133. Epub 2016 Apr 22.
7
[Expression of fatty acid synthase and adipocyte fatty acid-binding protein and the relationship with the clinicopathological characteristics in human infiltrating ductal breast cancer].[脂肪酸合酶和脂肪细胞脂肪酸结合蛋白在人浸润性导管乳腺癌中的表达及其与临床病理特征的关系]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2015 Mar;46(2):228-33.
8
Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.G蛋白信号调节因子20与三阴性乳腺癌的临床病理特征及预后相关。
Biochem Biophys Res Commun. 2017 Apr 8;485(3):693-697. doi: 10.1016/j.bbrc.2017.02.106. Epub 2017 Feb 22.
9
c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.基底样和非基底样三阴性乳腺癌中c-Met和ERβ的表达差异
Tumour Biol. 2016 Aug;37(8):11385-95. doi: 10.1007/s13277-016-5010-5. Epub 2016 Mar 11.
10
SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.SIRT1通过靶向上皮-间质转化相关途径诱导肿瘤侵袭，并且是三阴性乳腺癌中的一个预后标志物。
Tumour Biol. 2016 Apr;37(4):4743-53. doi: 10.1007/s13277-015-4231-3. Epub 2015 Oct 30.

引用本文的文献

1
SREBP1-Dependent Metabolism as a Potential Target for Breast Cancer Risk Reduction.作为降低乳腺癌风险潜在靶点的固醇调节元件结合蛋白1（SREBP1）依赖性代谢
Cancers (Basel). 2025 May 14;17(10):1664. doi: 10.3390/cancers17101664.
2
Cell death pathway regulation by fatty acid metabolism-related genes in neuroblastoma: a multi-omics analysis identifying CHD5 as a novel biomarker.脂肪酸代谢相关基因对神经母细胞瘤细胞死亡途径的调控：一项多组学分析确定CHD5为新型生物标志物
Discov Oncol. 2025 Mar 23;16(1):377. doi: 10.1007/s12672-025-02088-z.
3
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.

本文引用的文献

1
Atezolizumab in the treatment of metastatic triple-negative breast cancer.阿替利珠单抗治疗转移性三阴性乳腺癌。
Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
2
Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention.脂肪酸合酶在肿瘤起始中的新作用：对癌症预防的启示
Mol Cell Oncol. 2020 Jan 20;7(2):1709389. doi: 10.1080/23723556.2019.1709389. eCollection 2020.
3
The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.
脂质代谢重编程：乳腺癌进展和肿瘤微环境中被忽视的英雄。
Mol Cancer. 2025 Mar 3;24(1):61. doi: 10.1186/s12943-025-02258-1.
4
HE2Gene: image-to-RNA translation via multi-task learning for spatial transcriptomics data.HE2 基因：通过多任务学习进行空间转录组学数据的图像到 RNA 的翻译。
Bioinformatics. 2024 Jun 3;40(6). doi: 10.1093/bioinformatics/btae343.
5
Circadian clock and lipid metabolism disorders: a potential therapeutic strategy for cancer.昼夜节律钟与脂质代谢紊乱：癌症潜在的治疗策略。
Front Endocrinol (Lausanne). 2023 Dec 22;14:1292011. doi: 10.3389/fendo.2023.1292011. eCollection 2023.
6
Role of EGFR and FASN in breast cancer progression.表皮生长因子受体（EGFR）和脂肪酸合酶（FASN）在乳腺癌进展中的作用。
J Cell Commun Signal. 2023 Dec;17(4):1249-1282. doi: 10.1007/s12079-023-00771-w. Epub 2023 Jul 25.
7
Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: A systematic review and meta-analysis.脂肪酸合酶在乳腺癌中的预后及临床病理意义：一项系统评价与荟萃分析
Front Oncol. 2023 Apr 12;13:1153076. doi: 10.3389/fonc.2023.1153076. eCollection 2023.
8
Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of mA Modification.鉴定代谢相关蛋白作为胰岛素抵抗的生物标志物及其 mA 修饰的潜在机制。
Nutrients. 2023 Apr 11;15(8):1839. doi: 10.3390/nu15081839.
9
Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker.脂肪酸代谢与胃癌免疫微环境变化有关，RGS2 是一种新的肿瘤标志物。
Front Immunol. 2022 Dec 14;13:1065927. doi: 10.3389/fimmu.2022.1065927. eCollection 2022.
10
Proteomics-Based Identification of Dysregulated Proteins in Breast Cancer.基于蛋白质组学的乳腺癌中失调蛋白的鉴定
Proteomes. 2022 Oct 21;10(4):35. doi: 10.3390/proteomes10040035.
c-Met 作为非小细胞肺癌固有和获得性耐药的生物标志物和参与者的作用：两种新的突变值得进一步研究。
Molecules. 2019 Dec 4;24(24):4443. doi: 10.3390/molecules24244443.
4
EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming.EGFL9 通过诱导 cMET 激活和代谢重编程促进乳腺癌转移。
Nat Commun. 2019 Nov 6;10(1):5033. doi: 10.1038/s41467-019-13034-3.
5
FEN1 mediates miR-200a methylation and promotes breast cancer cell growth MET and EGFR signaling.FEN1 介导 miR-200a 甲基化并促进乳腺癌细胞生长的 MET 和 EGFR 信号。
FASEB J. 2019 Oct;33(10):10717-10730. doi: 10.1096/fj.201900273R. Epub 2019 Jul 2.
6
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.c-MET 作为手术切除的非小细胞肺癌患者的生物标志物。
Lung Cancer. 2019 Jul;133:69-74. doi: 10.1016/j.lungcan.2019.04.028. Epub 2019 May 1.
7
Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.抑制 FASN 通过调节葡萄糖代谢和 AKT/ERK 通路抑制非小细胞肺癌细胞的恶性生物学行为。
Lipids Health Dis. 2019 May 24;18(1):118. doi: 10.1186/s12944-019-1058-8.
8
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.达沙替尼治疗可增加三阴性乳腺癌细胞对c-Met抑制的敏感性。
Cancers (Basel). 2019 Apr 17;11(4):548. doi: 10.3390/cancers11040548.
9
Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics.运用综合生物信息学鉴定前列腺癌中异常甲基化的差异表达基因。
Cancer Cell Int. 2019 Mar 5;19:51. doi: 10.1186/s12935-019-0763-8. eCollection 2019.
10
c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells.c-Src 募集参与 c-MET 介导的 NT2D1 非精原细胞瘤细胞的恶性行为。
Int J Mol Sci. 2019 Jan 14;20(2):320. doi: 10.3390/ijms20020320.